
Valuation In Life Sciences: A Practical Guide
This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. After guiding the reader through the theory of valuation, including discounted cash-flow...
Hardcover: 249 pages
Publisher: Springer; 1 edition (February 21, 2007)
Language: English
ISBN-10: 3540455655
ISBN-13: 978-3540455653
Product Dimensions: 6.1 x 0.6 x 9.2 inches
Amazon Rank: 5089706
Format: PDF ePub djvu book
- 3540455655 pdf
- 978-3540455653 epub
- Boris Bogdan epub
- Boris Bogdan ebooks
- pdf books
Read Eclipse warriors power of three 4 ebook allpronpeimat.wordpress.com Download The key o it all pdf at oihfg.wordpress.com Richelle mea thorn queen The ghosts o cannae Here Awoboaloobo pdf link Read The friendly persuasion ebook americanchessbogany.wordpress.com Lexible ieting liestyle Download Generation earn pdf at businessplannirahigh.wordpress.com The photographers eye
and real options, the authors demonstrate how to value projects, patents, licences, firms and stocks on real-life examples, even treating complex licence and company structures. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results. Ralph Villiger and Boris Bogdan have written what is sure to become the industry standard reference for valuation of pharmaceutical and biotechnology projects and companies. At a time when the healthcare industry is placing increasing emphasis on licensing and M&A as a core strategy this book provides a firm understanding of the way in which products and businesses can be valued at all stages of their development.Dr. Martin Buckland, Chief Business Officer, Astex Therapeutics, Cambridge, UKThe book presents a number of innovative ideas, illustrated with practical examples that should improve decision-making in the drug development process, intellectual property evaluation, licensing and sublicensing. The authors make a persuasive case for the use of advanced techniques and the section on worked-examples should be particularly appealing to practitioners.Dr. Martin Grossmann, Novartis PharmaceuticalsThere is no doubt that this book will become an essential reference tool for professionals in technology transfer, business developers and biotech companies, as well as the pharmaceutical industry and Life Science investors.Jean-Pierre Saintouil, Director of Technology Transfer Department, Institut Pasteur, Paris, France
Leave a Comment